288 related articles for article (PubMed ID: 19052162)
1. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.
Camire AC; Hatke AL; King VL; Millership J; Ritter DM; Sobell N; Weber A; Marconi RT
Vet J; 2021 Jul; 273():105676. PubMed ID: 34148599
[TBL] [Abstract][Full Text] [Related]
3. One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin.
LaFleur RL; Callister SM; Dant JC; Jobe DA; Lovrich SD; Warner TF; Wasmoen TL; Schell RF
Clin Vaccine Immunol; 2010 May; 17(5):870-4. PubMed ID: 20237200
[TBL] [Abstract][Full Text] [Related]
4. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
5. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.
Conlon JA; Mather TN; Tanner P; Gallo G; Jacobson RH
Vet Ther; 2000; 1(2):96-107. PubMed ID: 19757556
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
8. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum.
Wagner B; Freer H; Rollins A; Erb HN
Vet Immunol Immunopathol; 2011 Apr; 140(3-4):190-8. PubMed ID: 21208663
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
Grosenbaugh DA; Rissi DR; Krimer PM
Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
[TBL] [Abstract][Full Text] [Related]
10. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
Izac JR; Oliver LD; Earnhart CG; Marconi RT
Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.
LaFleur RL; Callister SM; Dant JC; Wasmoen TL; Jobe DA; Lovrich SD
Clin Vaccine Immunol; 2015 Jul; 22(7):836-9. PubMed ID: 25972405
[TBL] [Abstract][Full Text] [Related]
12. Resistance to tick-borne spirochete challenge induced by Borrelia burgdorferi strains that differ in expression of outer surface proteins.
Kurtti TJ; Munderloh UG; Hughes CA; Engstrom SM; Johnson RC
Infect Immun; 1996 Oct; 64(10):4148-53. PubMed ID: 8926082
[TBL] [Abstract][Full Text] [Related]
13. Tick-Tattoo: DNA Vaccination Against
Klouwens MJ; Trentelman JJA; Wagemakers A; Ersoz JI; Bins AD; Hovius JW
Front Immunol; 2021; 12():615011. PubMed ID: 33717102
[TBL] [Abstract][Full Text] [Related]
14. Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.
Rhodes DV; Earnhart CG; Mather TN; Meeus PF; Marconi RT
Vet J; 2013 Nov; 198(2):412-8. PubMed ID: 23962611
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of horses with Lyme vaccines for dogs induces short-lasting antibody responses.
Guarino C; Asbie S; Rohde J; Glaser A; Wagner B
Vaccine; 2017 Jul; 35(33):4140-4147. PubMed ID: 28668566
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
[TBL] [Abstract][Full Text] [Related]
17. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.
Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA
Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289
[TBL] [Abstract][Full Text] [Related]
18. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
Lovrich SD; Jobe DA; Schell RF; Callister SM
Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
[TBL] [Abstract][Full Text] [Related]
19. Antibody responses to Borrelia burgdorferi outer surface proteins C and F in experimentally infected Beagle dogs.
Callister SM; LaFleur RL; Jobe DA; Lovrich SD; Wasmoen TL
J Vet Diagn Invest; 2015 Jul; 27(4):526-30. PubMed ID: 26069225
[TBL] [Abstract][Full Text] [Related]
20. Multiple antigen target approach using the Accuplex4 BioCD system to detect Borrelia burgdorferi antibodies in experimentally infected and vaccinated dogs.
Moroff S; Woodruff C; Woodring T; Sokolchik I; Lappin MR
J Vet Diagn Invest; 2015 Sep; 27(5):581-8. PubMed ID: 26289718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
